Worldwide Clinical Trials is expanding its horizons with the acquisition of Catalyst Clinical Research, a specialist oncology ...

The dyad model fosters collaboration between academic specialists and community oncologists, ensuring seamless patient care and eliminating geographic barriers. W. Kimryn Rathmell, MD, PhD, FASCO, ...

The acquisition aims to establish Worldwide as an oncology-focused CRO and expand its global reach for clinical trials.

Strategy is feasible for advanced cancers; 157 regimens were administered to 210 patients, including 103 personalized combos ...

Researchers at Mount Sinai launch a new AI platform to match more cancer patients with clinical trials, aiming to expand ...

National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple ...

A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...

SynOx Therapeutics completed enrollment for the phase 3 TANGENT study of emactuzumab for tenosynovial giant cell tumors, with results expected in 2026. ALX Oncology launched a phase 1 trial of ALX2004 ...

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Eligible patients ...

Texas Oncology is now offering Texoma residents access to clinical trials for cancer treatment. Texas Oncology provides ...